Who is sponsoring NCT01100502?

NCT01100502 is sponsored by Seagen Inc..

What condition does NCT01100502 study?

NCT01100502 studies Disease, Hodgkin.

What drugs are being tested in NCT01100502?

Interventions: brentuximab vedotin, placebo.

What is the status of NCT01100502?

NCT01100502 is currently COMPLETED.

Last reviewed 2021-05-14 · How we verify

A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

NCT01100502 PHASE3 COMPLETED Results posted

This is a randomized, double-blind, placebo-controlled, multicenter phase 3 trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) and best supportive care (BSC) compared to placebo and BSC in treatment of residual Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT).

Details

Lead sponsor	Seagen Inc.
Phase	PHASE3
Status	COMPLETED
Enrolment	329
Start date	Fri Apr 30 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Apr 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Disease, Hodgkin

Interventions

brentuximab vedotin
placebo

Countries

France, Italy, Russia, Serbia, United Kingdom, Germany, Hungary, Poland, Romania, Bulgaria, United States, Spain, Czechia